FDA approves Klygefa (gefurulimab) for generalised myasthenia gravis in adults – AstraZeneca
The US Food and Drug Administration (FDA) has approved Klygefa (gefurulimab), from Alexion, AstraZeneca Rare Disease, for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor approved in the US. Patients give it to themselves once a week by subcutaneous autoinjector.
PREVAIL Phase III results
The approval is based on the global PREVAIL Phase III trial. This randomised, double-blind, placebo-controlled study enrolled 260 adults with AChR antibody-positive gMG from 20 countries. Patients were randomised 1:1 to Klygefa or placebo for 26 weeks. They received a weight-based loading dose on Day 1, then weekly maintenance doses from Day 8.
Klygefa met its primary endpoint. It improved Myasthenia Gravis Activities of Daily Living (MG-ADL) total score from baseline to week 26 compared with placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). Improvement was seen as early as week one and was sustained through one year. The data were presented at the AANEM 2025 Annual Meeting and published in JAMA Neurology.
Safety
Klygefa was generally well tolerated. Its safety profile was consistent with earlier gMG trials of the C5 inhibitors eculizumab and ravulizumab. Rates of treatment-emergent adverse events were similar with Klygefa and placebo, and most were mild to moderate. The most common were injection site reactions (12%), back pain (8%) and vomiting (5%).
How it works
Klygefa binds the C5 protein in the terminal complement cascade. In AChR antibody-positive gMG, this cascade drives the immune attack on the neuromuscular junction. Klygefa also binds serum albumin, which extends its half-life and allows once-weekly dosing.
“With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition,” said Kelly Gwathmey, MD, a principal investigator in the trial.
In the US, an estimated 98,500 people are diagnosed with gMG, and 81,000 of them are AChR-positive. Klygefa is already approved in the EU, Japan and other countries. Regulatory submissions are under review in China and elsewhere.




